Eli Lilly (LLY) Common Equity (2009 - 2026)

Eli Lilly has reported Common Equity for 18 years, with the latest figure at $31.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 106.61% year-over-year to $31.2 billion; the trailing twelve-month figure through Mar 2026 stood at $31.2 billion (up 106.61% YoY), and the FY2025 full-year result was $26.5 billion, up 1210.25% from the prior year.
• Common Equity for Q1 2026 stood at $31.2 billion, up from $26.5 billion in the prior quarter.
• The five-year high for Common Equity was $31.2 billion in Q1 2026, with the low at -$3.8 billion in Q4 2022.
• Historically, Common Equity has averaged $4.6 billion across 5 years, with a median of -$2.2 billion in 2025.
• The largest YoY upside for Common Equity was 46277.37% in 2025 against a maximum downside of 6607.65% in 2025.
• Eli Lilly's Common Equity stood at -$3.8 billion in 2022, then climbed by 29.86% to -$2.7 billion in 2023, then gained by 11.38% to -$2.4 billion in 2024, then jumped by 1210.25% to $26.5 billion in 2025, then grew by 17.57% to $31.2 billion in 2026.
• The last three Common Equity figures came in at $31.2 billion (Q1 2026), $26.5 billion (Q4 2025), and $23.8 billion (Q3 2025), per Business Quant data.